The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
Marek Niedoszytko - One of the best experts on this subject based on the ideXlab platform.
-
The Role of TRAF4 and B3GAT1 Gene Expression in the Food Hypersensitivity and Insect Venom Allergy in Mastocytosis
Archivum Immunologiae et Therapiae Experimentalis, 2016Co-Authors: Aleksandra Górska, Marek Niedoszytko, Marta Chełmińska, Marta Gruchała-niedoszytko, Agnieszka Maciejewska, Marcin Skrzypski, Bartosz Wasąg, Małgorzata Kaczkan, Magdalena Lange, Bogusław NedoszytkoAbstract:Mastocytosis is an uncommon disease classified as a myeloproliferative neoplasm, however, its symptoms are broad and place patients at crossroads between dermatology, hematology and allergology. Patients with mastocytosis often suffer from symptoms resulting from the activation and release of mediators from the mast cells, such as generalized itching, redness, headache, abdominal cramps, diarrhea, bone pain or arthritis, hypotension and shock. The possible severe, fatal or near fatal reactions caused by food hypersensitivity are reasons for the research focused on marker identification. The aim of the study was to analyse the gene expression differences in mastocytosis patients with and without food and drug hypersensitivity and Insect Venom allergy (IVA). A total of 57 Caucasian patients with mastocytosis were studied [median age 41.8; range 18–77 years; 15 (26.3 %) males and 42 (73.7 %) females]. Quantitative RT-PCRs of 11 genes plus ribosomal 18S RNA were run. Symptoms of food hypersensitivity were found in 12 patients (21 %), including 3 patients (13 %) with cutaneous mastocytosis (CM), and 9 (28 %) with indolent systemic mastocytosis (ISM). IVA was confirmed in 13 patients (22.8 %) including 6 patients (10.5 %) with CM, and 7 patients (12.3 %) with ISM. Drug hypersensitivity was diagnosed in 10 patients (17.5 %). Significant differences in the gene expression were found for TRAF4 ( p = 0.008) in the comparison of the mastocytosis patients with and without concomitant food hypersensitivity. Furthermore significant differences were found in gene expression for B3GAT1 ( p = 0.003) in patients with IVA compared to patients without Insect sting anaphylaxis in the medical history. The expression of studied genes did not differ according to the presence of drug hypersensitivity. The TRAF4 expression was higher in mastocytosis patients with food hypersensitivity in their medical history, the B3GAT1 expression was lower in mastocytosis patients with IVA in history.
-
quality of life anxiety depression and satisfaction with life in patients treated with Insect Venom immunotherapy
2012Co-Authors: Marek Niedoszytko, Ewa Jassem, Tomasz Buss, Marta Gruchalaniedoszytko, Monika Lichodziejewskaniemierko, Sylwia MalgorzewiczAbstract:Introduction: Insect Venom allergy (IVA) is related to a higher risk of life-threatening anaphylactic reactions, result ing in decreased quality of life (QoL). Aim: The aim of the study is to: (1) assess the QoL, anxiety and depression among patients treated with Venom immunotherapy (VIT) and influence of VIT on the QoL, (2) compare patients with improvement and deterioration in VQLQ during VIT and (3) to assess QoL among bee Venom allergic patients. Material and methods: A total of 71 patients with VIT were studied. The following questionnaires were used (before and after 1 year of VIT): HADS (Hospital Anxiety and Depression), STAI (Spielberg State-Trait Anxiety Inventory for Adults), Cantril's Self-Anchoring Ladder, VQLQ (Vespid Allergy Quality of Life Questionnaire). Results: The VQLQ before VIT for wasp allergic patients was 3.7 (SD = 1.9) and improved after 1 year of VIT to 4.3 (SD = 1.9), p = 0.007. Improvement of VQLQ was found in 23 subjects (44%), and deterioration in 8 (15%) wasp aller gic patients. The VQLQ of patients who experienced deterioration in VQLQ was significantly higher before VIT than the remaining patients, p = 0.001. Pathological anxiety was diagnosed in 23 subjects (33%). Validation of the ques tionnaire was not possible for bee allergic patients. Conclusions: Quality of life of Polish IVA patients is comparable to other populations. Anxiety, not depression, was more prevalent in IVA patients than in the general population. The therapy improves QoL, especially in women and patients with impaired QoL before treatment. The VQLQ questionnaire has been validated among Polish patients allergic to wasp and not bee Venom.
-
changes in gene expression caused by Insect Venom immunotherapy responsible for the long term protection of Insect Venom allergic patients
Annals of Allergy Asthma & Immunology, 2011Co-Authors: Marek Niedoszytko, Marcel Bruinenberg, Jan G R De Monchy, Rinse K Weersma, Cisca Wijmenga, Ewa Jassem, Joanne Oude N G ElberinkAbstract:Background Insect Venom immunotherapy (VIT) is the only causative treatment of Insect Venom allergy (IVA). The immunological mechanism(s) responsible for long-term protection achieved by VIT are largely unknown. A better understanding is relevant for improving the diagnosis, prediction of anaphylaxis, and monitoring and simplifying treatment of IVA. Objective To find genes that are differentially expressed during the maintenance phase of VIT and after stopping, to get clues about the pathways involved in the long-term protective effect of immunotherapy. Methods Whole genome gene expression analysis was performed on RNA samples from 50 patients treated with VIT and 43 healthy controls. Patients were divided into three groups: (1) before the start of VIT; (2) on maintenance phase of VIT for at least 3 years still receiving injections; and (3) after VIT. Results Of all 48,804 probes present in the array, 48,773 transcripts had sufficient data for further analysis. The list of genes that were differentially expressed (at least log2 FC > 2; P Conclusion This study shows that a group of genes is differentially expressed both during and after VIT in comparison with gene expression in patients before VIT. Although the results of this study should be confirmed prospectively, the relevance of these findings is supported by the fact that they are related to putative mechanisms of immunotherapy.
-
gene expression analysis predicts Insect Venom anaphylaxis in indolent systemic mastocytosis
Allergy, 2011Co-Authors: Marek Niedoszytko, Marcel Bruinenberg, Cisca Wijmenga, J J Van Doormaal, J G R De Monchy, Boguslaw Nedoszytko, Gerard H Koppelman, Martijn C Nawijn, Ewa JassemAbstract:Background: Anaphylaxis to Insect Venom (Hymenoptera) is most severe in patients with mastocytosis and may even lead to death. However, not all patients with mastocytosis suffer from anaphylaxis. The aim of the study was to analyze differences in gene expression between patients with indolent systemic mastocytosis (ISM) and a history of Insect Venom anaphylaxis (IVA) compared to those patients without a history of anaphylaxis, and to determine the predictive use of gene expression profiling. Methods: Whole-genome gene expression analysis was performed in peripheral blood cells. Results: Twenty-two adults with ISM were included: 12 with a history of IVA and 10 without a history of anaphylaxis of any kind. Significant differences in single gene expression corrected for multiple testing were found for 104 transcripts (P < 0.05). Gene ontology analysis revealed that the differentially expressed genes were involved in pathways responsible for the development of cancer and focal and cell adhesion suggesting that the expression of genes related to the differentiation state of cells is higher in patients with a history of anaphylaxis. Based on the gene expression (%)
-
Changes in gene expression caused by Insect Venom immunotherapy responsible for the long-term protection of Insect Venom–allergic patients
Annals of Allergy Asthma & Immunology, 2011Co-Authors: Marek Niedoszytko, Marcel Bruinenberg, Jan G R De Monchy, Rinse K Weersma, Cisca Wijmenga, Ewa Jassem, Joanne Oude N G ElberinkAbstract:Background Insect Venom immunotherapy (VIT) is the only causative treatment of Insect Venom allergy (IVA). The immunological mechanism(s) responsible for long-term protection achieved by VIT are largely unknown. A better understanding is relevant for improving the diagnosis, prediction of anaphylaxis, and monitoring and simplifying treatment of IVA. Objective To find genes that are differentially expressed during the maintenance phase of VIT and after stopping, to get clues about the pathways involved in the long-term protective effect of immunotherapy. Methods Whole genome gene expression analysis was performed on RNA samples from 50 patients treated with VIT and 43 healthy controls. Patients were divided into three groups: (1) before the start of VIT; (2) on maintenance phase of VIT for at least 3 years still receiving injections; and (3) after VIT. Results Of all 48,804 probes present in the array, 48,773 transcripts had sufficient data for further analysis. The list of genes that were differentially expressed (at least log2 FC > 2; P Conclusion This study shows that a group of genes is differentially expressed both during and after VIT in comparison with gene expression in patients before VIT. Although the results of this study should be confirmed prospectively, the relevance of these findings is supported by the fact that they are related to putative mechanisms of immunotherapy.
U Muller - One of the best experts on this subject based on the ideXlab platform.
-
mastocytosis and Insect Venom allergy
Current Opinion in Allergy and Clinical Immunology, 2010Co-Authors: Patrizia Bonadonna, Roberta Zanotti, U MullerAbstract:Purpose of review To analyse the association of systemic allergic hymenoptera sting reactions with mastocytosis and elevated baseline serum tryptase and to discuss diagnosis and treatment in patients with both diseases. Recent findings In recent large studies on patients with mastocytosis a much higher incidence of severe anaphylaxis following hymenoptera stings than in the normal population was documented. In patients with hymenoptera Venom allergy, elevated baseline tryptase is strongly associated with severe anaphylaxis. Fatal sting reactions were reported in patients with mastocytosis, notably after stopping Venom immunotherapy. During Venom immunotherapy most patients with mastocytosis are protected from further sting reactions. Based on these observations immunotherapy for life is recommended for patients with mastocytosis and Venom allergy. The incidence of allergic side-effects is increased in patients with mastocytosis and elevated baseline tryptase, especially in those allergic to Vespula Venom. Premedication with antihistamines, or omalizumab in cases with recurrent severe side-effects, can be helpful. Summary In all patients with anaphylaxis following hymenoptera stings, baseline serum tryptase should be determined. A value above 11.4 microg/l is often due to mastocytosis and indicates a high risk of very severe anaphylaxis following re-stings. Venom immunotherapy is safe and effective in this situation.
-
recent developments and future strategies for immunotherapy of Insect Venom allergy
Current Opinion in Allergy and Clinical Immunology, 2003Co-Authors: U MullerAbstract:PURPOSE OF REVIEW: Hymenoptera Venom allergy may cause life-threatening, sometimes even fatal, allergic reactions and thus may be associated with a serious reduction in the quality of life. Venom immunotherapy is effective in the majority of patients with this allergy. Treatment failures do however occur and immunotherapy may cause frequent systemic allergic side effects, especially in honeybee Venom-allergic patients. New strategies to improve safety and efficacy of this treatment are therefore of general interest. RECENT FINDINGS: Among these new strategies are premedication with antihistamines: this definitely reduces side effects and based on recent in-vitro experiments and one clinical controlled study may even improve efficacy by modulating the T-cell response through interference with histamine receptors on these cells. Furthermore, during recent years the cDNA of most major allergens of bee and vespid Venoms has been cloned and these allergens have been expressed in recombinant form. This allows for the preparation of patient-tailored extracts, with or without reduction of their allergenicity, for example by using unrefolded or point-mutated recombinant allergens. Yet another approach is the use of non IgE binding peptide fragments of the allergen with preserved T-cell epitopes for immunotherapy. Such preparations of bee Venom phospholipase A2 have been used successfully in pilot studies. Finally, DNA vaccination with phospholipase A2 sequence plasmids has proved effective in one experimental study in sensitized mice. SUMMARY: A number of new strategies for Venom immunotherapy, mostly based on genetic engineering, have been described and we await their use in clinical medicine.
-
Side-effects of Insect Venom immunotherapy:results from an EAACI multicenter study: Side-effects of Insect Venom immunotherapy
Allergy, 2000Co-Authors: H. Mosbech, U MullerAbstract:BACKGROUND: The effect of Venom immunotherapy (VIT) is well documented, but fear of systemic side-effects (SE) may prevent its use. The study aimed to analyze the character and frequency of SE and risk factors. METHODS: In a prospective study, 19 European centers included patients starting on VIT for systemic reactions to Insect stings. Various dose regimens were applied. RESULTS: Data from 840 patients with a total of 26 601 injections were obtained. Seventy-one percent were treated with Vespula-Venom extract and 27% with honeybee-Venom extract. Twenty percent of patients had SE corresponding to 1.9% of injections during dose increase and 0.5% during the maintenance phase. The vast majority of the 280 reactions were mild: only one-third required medical treatment. Injected or inhaled adrenaline was applied in six patients, of whom only one had a drop in blood pressure and collapse. Female sex, bee-Venom extract, and rapid dose increase, but not severity of Insect sting reactions, increased the risk of SE. The severity of SE was less in males but was not related to age, treatment phase, species of Insect, or severity of Insect sting reactions. CONCLUSIONS: The frequency of SE was low, and the majority of these could be managed without treatment. Risk was increased in females, in bee-Venom-treated patients, and in those with rapid dose increase.
-
side effects of Insect Venom immunotherapy results from an eaaci multicenter study
Allergy, 2000Co-Authors: H. Mosbech, U MullerAbstract:Background: The effect of Venom immunotherapy (VIT) is well documented, but fear of systemic side-effects (SE) may prevent its use. The study aimed to analyze the character and frequency of SE and risk factors. Methods: In a prospective study, 19 European centers included patients starting on VIT for systemic reactions to Insect stings. Various dose regimens were applied. Results: Data from 840 patients with a total of 26601 injections were obtained. Seventy-one percent were treated with Vespula-Venom extract and 27% with honeybee-Venom extract. Twenty percent of patients had SE corresponding to 1.9% of injections during dose increase and 0.5% during the maintenance phase. The vast majority of the 280 reactions were mild: only one-third required medical treatment. Injected or inhaled adrenaline was applied in six patients, of whom only one had a drop in blood pressure and collapse. Female sex, bee-Venom extract, and rapid dose increase, but not severity of Insect sting reactions, increased the risk of SE. The severity of SE was less in males but was not related to age, treatment phase, species of Insect, or severity of Insect sting reactions. Conclusions: The frequency of SE was low, and the majority of thesecould be managed without treatment. Risk was increased in females, in bee-Venom-treated patients, and in those with rapid dose increase.
-
the sting challenge test in hymenoptera Venom allergy position paper of the subcommittee on Insect Venom allergy of the european academy of allergology and clinical immunology
Allergy, 1996Co-Authors: Franziska Ruëff, Bernhard Przybilla, U Muller, Holger MosbechAbstract:Rueff F, Przybilla B, Muller U, Mosbech H. The sting challenge test in Hymenoptera Venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy 1996: 51: 216–225. © Munksgaard 1996.
Ewa Jassem - One of the best experts on this subject based on the ideXlab platform.
-
quality of life anxiety depression and satisfaction with life in patients treated with Insect Venom immunotherapy
2012Co-Authors: Marek Niedoszytko, Ewa Jassem, Tomasz Buss, Marta Gruchalaniedoszytko, Monika Lichodziejewskaniemierko, Sylwia MalgorzewiczAbstract:Introduction: Insect Venom allergy (IVA) is related to a higher risk of life-threatening anaphylactic reactions, result ing in decreased quality of life (QoL). Aim: The aim of the study is to: (1) assess the QoL, anxiety and depression among patients treated with Venom immunotherapy (VIT) and influence of VIT on the QoL, (2) compare patients with improvement and deterioration in VQLQ during VIT and (3) to assess QoL among bee Venom allergic patients. Material and methods: A total of 71 patients with VIT were studied. The following questionnaires were used (before and after 1 year of VIT): HADS (Hospital Anxiety and Depression), STAI (Spielberg State-Trait Anxiety Inventory for Adults), Cantril's Self-Anchoring Ladder, VQLQ (Vespid Allergy Quality of Life Questionnaire). Results: The VQLQ before VIT for wasp allergic patients was 3.7 (SD = 1.9) and improved after 1 year of VIT to 4.3 (SD = 1.9), p = 0.007. Improvement of VQLQ was found in 23 subjects (44%), and deterioration in 8 (15%) wasp aller gic patients. The VQLQ of patients who experienced deterioration in VQLQ was significantly higher before VIT than the remaining patients, p = 0.001. Pathological anxiety was diagnosed in 23 subjects (33%). Validation of the ques tionnaire was not possible for bee allergic patients. Conclusions: Quality of life of Polish IVA patients is comparable to other populations. Anxiety, not depression, was more prevalent in IVA patients than in the general population. The therapy improves QoL, especially in women and patients with impaired QoL before treatment. The VQLQ questionnaire has been validated among Polish patients allergic to wasp and not bee Venom.
-
changes in gene expression caused by Insect Venom immunotherapy responsible for the long term protection of Insect Venom allergic patients
Annals of Allergy Asthma & Immunology, 2011Co-Authors: Marek Niedoszytko, Marcel Bruinenberg, Jan G R De Monchy, Rinse K Weersma, Cisca Wijmenga, Ewa Jassem, Joanne Oude N G ElberinkAbstract:Background Insect Venom immunotherapy (VIT) is the only causative treatment of Insect Venom allergy (IVA). The immunological mechanism(s) responsible for long-term protection achieved by VIT are largely unknown. A better understanding is relevant for improving the diagnosis, prediction of anaphylaxis, and monitoring and simplifying treatment of IVA. Objective To find genes that are differentially expressed during the maintenance phase of VIT and after stopping, to get clues about the pathways involved in the long-term protective effect of immunotherapy. Methods Whole genome gene expression analysis was performed on RNA samples from 50 patients treated with VIT and 43 healthy controls. Patients were divided into three groups: (1) before the start of VIT; (2) on maintenance phase of VIT for at least 3 years still receiving injections; and (3) after VIT. Results Of all 48,804 probes present in the array, 48,773 transcripts had sufficient data for further analysis. The list of genes that were differentially expressed (at least log2 FC > 2; P Conclusion This study shows that a group of genes is differentially expressed both during and after VIT in comparison with gene expression in patients before VIT. Although the results of this study should be confirmed prospectively, the relevance of these findings is supported by the fact that they are related to putative mechanisms of immunotherapy.
-
gene expression analysis predicts Insect Venom anaphylaxis in indolent systemic mastocytosis
Allergy, 2011Co-Authors: Marek Niedoszytko, Marcel Bruinenberg, Cisca Wijmenga, J J Van Doormaal, J G R De Monchy, Boguslaw Nedoszytko, Gerard H Koppelman, Martijn C Nawijn, Ewa JassemAbstract:Background: Anaphylaxis to Insect Venom (Hymenoptera) is most severe in patients with mastocytosis and may even lead to death. However, not all patients with mastocytosis suffer from anaphylaxis. The aim of the study was to analyze differences in gene expression between patients with indolent systemic mastocytosis (ISM) and a history of Insect Venom anaphylaxis (IVA) compared to those patients without a history of anaphylaxis, and to determine the predictive use of gene expression profiling. Methods: Whole-genome gene expression analysis was performed in peripheral blood cells. Results: Twenty-two adults with ISM were included: 12 with a history of IVA and 10 without a history of anaphylaxis of any kind. Significant differences in single gene expression corrected for multiple testing were found for 104 transcripts (P < 0.05). Gene ontology analysis revealed that the differentially expressed genes were involved in pathways responsible for the development of cancer and focal and cell adhesion suggesting that the expression of genes related to the differentiation state of cells is higher in patients with a history of anaphylaxis. Based on the gene expression (%)
-
Changes in gene expression caused by Insect Venom immunotherapy responsible for the long-term protection of Insect Venom–allergic patients
Annals of Allergy Asthma & Immunology, 2011Co-Authors: Marek Niedoszytko, Marcel Bruinenberg, Jan G R De Monchy, Rinse K Weersma, Cisca Wijmenga, Ewa Jassem, Joanne Oude N G ElberinkAbstract:Background Insect Venom immunotherapy (VIT) is the only causative treatment of Insect Venom allergy (IVA). The immunological mechanism(s) responsible for long-term protection achieved by VIT are largely unknown. A better understanding is relevant for improving the diagnosis, prediction of anaphylaxis, and monitoring and simplifying treatment of IVA. Objective To find genes that are differentially expressed during the maintenance phase of VIT and after stopping, to get clues about the pathways involved in the long-term protective effect of immunotherapy. Methods Whole genome gene expression analysis was performed on RNA samples from 50 patients treated with VIT and 43 healthy controls. Patients were divided into three groups: (1) before the start of VIT; (2) on maintenance phase of VIT for at least 3 years still receiving injections; and (3) after VIT. Results Of all 48,804 probes present in the array, 48,773 transcripts had sufficient data for further analysis. The list of genes that were differentially expressed (at least log2 FC > 2; P Conclusion This study shows that a group of genes is differentially expressed both during and after VIT in comparison with gene expression in patients before VIT. Although the results of this study should be confirmed prospectively, the relevance of these findings is supported by the fact that they are related to putative mechanisms of immunotherapy.
-
the angiotensinogen agt p m235t gene polymorphism may be responsible for the development of severe anaphylactic reactions to Insect Venom allergens
International Archives of Allergy and Immunology, 2010Co-Authors: Marek Niedoszytko, Magdalena Ratajska, Michał Makowiecki, Ewelina Malek, Janusz Limon, Marta Chelminska, Alicja Sieminska, Ewa JassemAbstract:Background: Insect Venom allergy (IVA) is present in 1–3% of the population. A group of patients with high specific IgE do not react to stings. In contrast, a proportion of patients with IVA have low specific IgE levels. These findings indicate that factors other than specific IgE may also be involved in IVA. Dysfunction of the renin-angiotensin system (RAS) has been described as a potential factor in IVA. The objective of this study was to determine the prevalence of angiotensin AGT p.M235T and angiotensin-converting enzyme ACE I/D, I/I, D/D gene polymorphisms in patients with IVA and to relate the presence of these gene variants to the course of IVA and the safety of treatment. Methods: A total of 107 patients with IVA and 113 controls were studied. AGT p.M235T and ACE (ID, I/I, D/D) gene polymorphisms were examined, and angiotensin I levels were measured by immunoassay. Results: The frequency of the AGT MM M235T variant was significantly higher in IVA patients (29.9%) than in controls (17%, p = 0.02). The presence of the MM M235T genotype increased the risk of grade IV reactions (odds ratio = 2.5 and 95% confidence interval 1.04–6.08). There were no differences in the prevalence of the ACE I/D polymorphism and angiotensin I levels between control groups and patients with different grades of anaphylactic reactions or patients with side effects of Venom immunotherapy. Conclusion: The AGT M235T MM variant may be responsible for severe anaphylactic reactions to Insect Venom allergens in some patients.
Te Piao King - One of the best experts on this subject based on the ideXlab platform.
-
hyaluronidase and hyaluronan in Insect Venom allergy
International Archives of Allergy and Immunology, 2011Co-Authors: Te Piao King, Knut M WittkowskiAbstract:BACKGROUND: Insect Venoms contain an allergen hyaluronidase that catalyzes the hydrolysis of hyaluronan (HA), a polymer of disaccharide GlcUA-GlcNAc in skin. HAs depending on their size have variable function in inflammation and immunity. This paper reports on whether hyaluronidase, HA polymers and oligomers can promote antibody response in mice. METHODS: HA oligomers (8- to 50-mer; 3-20 kDa) were obtained by bee Venom hyaluronidase digestion of HA polymers (750- to 5,000-mer; 300-2,000 kDa). Antibody responses in mice were compared following 3 biweekly subcutaneous injection of ovalbumin (OVA) with or without test adjuvant. RESULTS: OVA-specific IgG1 levels were approximately 2 times higher in BALB/c and C3H/HeJ mice receiving OVA and HA oligomer or polymer than those treated with OVA alone, and no increase in total IgE level was observed. In C57Bl/6 mice, observed increases in IgG1 and IgE were 3.5- and 1.7-fold, respectively, for the oligomer and 16- and 5-fold (p < 0.05), respectively, for the polymer. CONCLUSION: Hyaluronidase by its action on HA in skin can function indirectly as adjuvant to promote IgE and IgG1 response in mice. Insect Venoms also have cytolytic peptides and phospholipases with inflammatory roles. These activities found in mice may contribute to Venom allergenicity in susceptible people.
-
structure and biology of stinging Insect Venom allergens
International Archives of Allergy and Immunology, 2000Co-Authors: Te Piao King, Michael D SpangfortAbstract:Bees, fire ants and vespids cause Insect sting allergy. These Insects have unique as well as common Venom allergens. Vespids, including hornets, paper wasps and yellow jackets, have common allergens.
-
structure and biology of stinging Insect Venom allergens
International Archives of Allergy and Immunology, 2000Co-Authors: Te Piao King, Michael D SpangfortAbstract:Bees, fire ants and vespids cause Insect sting allergy. These Insects have unique as well as common Venom allergens. Vespids, including hornets, paper wasps and yellow jackets, have common allergens. Bees and vespids have one common allergen with hyaluronidase activity; they also have unique allergens with different phospholipase activities. Fire ants and vespids have one common allergen, antigen 5 of unknown biologic activity. The common Venom allergens with < 70% sequence identity have barely detectable levels of antigenic cross-reactivity. Possible uses of modified allergens for immunotherapy are described.
J Ring - One of the best experts on this subject based on the ideXlab platform.
-
comparison of basophil activation tests using cd63 or cd203c expression in patients with Insect Venom allergy
Allergy, 2006Co-Authors: B Eberleinkonig, H Behrendt, R Varga, Martin Mempel, U Darsow, J RingAbstract:BACKGROUND: Flow cytometric basophil activation tests have been developed as cellular tests for in vitro diagnosis of IgE-mediated reactions. Different activation markers (CD63 or CD203c) with distinct ways of regulation have been used after stimulation with various allergens. OBJECTIVE: It was the aim of the present study to compare basophil activation tests by measuring both CD63 and CD203c upregulation in patients with Insect Venom allergy. MATERIALS AND METHODS: 43 patients with a history of Insect Venom anaphylaxis were examined. A careful allergy history was taken, and skin tests and determination of specific IgE-antibodies were performed. Basophil activation tests (BAT) using CD63 or CD203c expression were done after stimulation with different concentrations of bee and wasp Venom extracts. 25 healthy subjects with negative history of Insect Venom allergy were studied as controls. RESULTS: The CD203c protocol showed a slightly higher sensitivity than the CD63 protocol (97% vs. 89%) with regard to patients' history. The magnitude of basophil response was higher with CD203c in comparison to CD63 for both Insect Venoms. Specificity was 100% for the CD63 protocol and 89% for the CD203c protocol with regard to controls with negative history and negative RAST. CONCLUSION: These results support the reliability of basophil activation tests using either CD63 or CD203c as cellular tests in the in vitro diagnosis of patients with bee or wasp Venom allergy with a slightly higher sensitivity for the CD203c protocol.
-
in vitro basophil activation using cd63 expression in patients with bee and wasp Venom allergy
Journal of Investigational Allergology and Clinical Immunology, 2006Co-Authors: B Eberleinkonig, C Schmidtleidescher, H Behrendt, Jurgen Rakoski, J RingAbstract:Summary. The diagnosis of Insect Venom allergy and the indication for specific immunotherapy is based on history, skin tests and demonstration of hymenoptera Venom-specific IgE-antibodies. Cellular tests can add useful information but the role of basophil activation tests for the different Venoms has to be elucidated further. We evaluated positive reactions in a basophil activation test using CD63 expression as marker independently for bee or wasp Venom in patients with hymenoptera allergy. Fifty-seven patients with a history of Insect Venom anaphylaxis were examined (12 x bee Venom, 39 x wasp Venom, 6 x bee plus wasp Venom). Skin tests and determination of specific IgE-antibodies were performed. Basophil activation test (BAT) using CD63 expression was performed after stimulation with different concentrations of bee and wasp Venom. The BAT is based on double staining with anti-IgE antibodies and anti-CD63 and subsequent determination of the percentage of activated basophils by flow cytometry. In patients with bee Venom allergy, BAT was positive in 100% to bee Venom and 75% to wasp Venom. In patients with bee and wasp Venom allergy, positive reactions for both Venoms were found in 100%. In patients with wasp Venom allergy, 97% reacted positive to wasp Venom and only 56% to bee Venom. These results show the reliability of the basophil activation test as a cellular test in the in vitro diagnosis in patients with bee and wasp Venom allergy. They also show that positive reactions in the basophil activation test reflect both sensitization status and cross-reactivity between Venom species.
-
use of cd63 expression as marker of in vitro basophil activation in identifying the culprit in Insect Venom allergy
Journal of Investigational Allergology and Clinical Immunology, 2004Co-Authors: B Eberleinkonig, H Behrendt, Jurgen Rakoski, J RingAbstract:BACKGROUND: The diagnosis of Insect Venom allergy and the indication for specific immunotherapy is based on history, skin tests and demonstration of hymenoptera Venom specific IgE-antibodies. In cases with contradictory test results additional cellular tests are recommended. OBJECTIVE: We evaluated the usefulness of a newly introduced test based on basophil CD63 expression as marker of activation in comparison with the basophil histamine release test (BHR) and the cellular antigen stimulation test (CAST) measuring leukotriene release. METHODS: In 14 patients (10 males, 4 females; age; 12 to 67 years, mean: 42.5 +/- 15.1 years) with systemic reactions to hymenoptera stings in their history skin tests and determination of specific IgE-antibodies (CAP-RAST-FEIA) had shown inconsistent results: No demonstration of specific IgE-antibodies (n = 4), one sting by an unknown Insect together with positive skin test and/or positive RAST to both bee and wasp Venom (n = 4), several stings of partly unknown Insects with positive skin test and/or demonstrable specific IgE-antibodies to more than one Insect Venom (n = 4), uncertain history and divergent results in skin test and/or RAST (n = 2). BHR, CAST and basophil activation test (BAT) were done according to the manufacturers with negative and positive controls and different concentrations of bee and wasp Venom. The BAT is based on double staining with anti-IgE antibodies and anti-CD63 and subsequent determination of the percentage of activated basophils by flow cytometry. RESULTS: BAT and skin test were concordant in 42.9%, BAT and RAST in 57.1%. Concordance of all three cellular tests was seen in 57.1%, of BAT and BHR in 69.1%, of BAT and CAST in 78.6% and of BHR and CAST in 64.3%. In 6 cases where the three cellular tests (BHR, CAST, BAT) were not in accordance the addition of BAT led to a more reliable diagnostic result concerning the relevant Insect in 3 cases and added no further information in 3 cases. BAT in controls always was negative. Correlation between CAST and BAT was higher than between CAST and BHR. CONCLUSIONS: In difficult cases of hymenoptera allergy, where history, skin tests and determination of specific antibodies do not allow a clear decision regarding the relevant Insect species for immunotherapy, the additional performance of cellular tests (CAST and BAT) may be helpful.